Abstract
Abstract Purpose Patients with Oligometastatic (OM) non-small-cell lung cancer (NSCLC) (≤ 3 metastases) might benefit from radical ablative treatment of both primary tumor and metastases. However, the role of ablative therapy in OM patients with locally advance primary tumor has not been evaluated. The aim of our study was to analyze the efficacy and safety of ablative treatment in patients with unresectable primary tumor and synchronous Oligometastases, in terms of response rate, progression free survival (PFS) and overall survival (OS). Methods/Patients Retrospective study of patients with Oligometastatic NSCLC (≤ 3 lesions in a unique location) and unresectable primary tumor, treated with radical intent (chemo-radiotherapy for primary tumor and surgery, radiotherapy, Stereotactic Body Radiation Therapy (SBRT) or radiofrequency for all known metastases) between October 2011 and March 2015. Results Thirty patients met inclusion criteria. Median age was 58 years, 76.6% were male, and 96.6% had ECOG 0-1. Histology: Adenocarcinoma (63.6%), squamous carcinoma (20%), and other histology (13.4%). All patients had unresectable primary tumor and/or mediastinal lymph nodes. Site of metastases: brain (46.6%), lung (23.3%), bone (20%), other locations (9.9%). Sequential thoracic radiotherapy (40%) and concomitant radiotherapy (60%). Treatment of metastases: SBRT (53.3%), external radiotherapy (26.6%), surgery (13.6%), radiofrequency (3.3%), none (3.3%). Toxicity grade 3 (29.4%). Response rate was 69.9%, median PFS 11.1 months (IC 95%: 8.2-13.7), and median OS 20.2 months (IC: 15.6-20.3). Conclusions Radical treatment for oligometastatic and unresectable NSCLC patients is a safe therapeutic strategy and it could be contemplated as an effective therapeutic alternative in selected patients.
Highlights
Non-Small-Cell Lung carcinoma (NSCLC) is the leading cause of cancer death worldwide [1]
Radical treatment for oligometastatic and unresectable NSCLC patients is a safe therapeutic strategy and it could be contemplated as an effective therapeutic alternative in selected patients
The objectives of this study were to analyze the efficacy and safety of ablative treatment in patients diagnosed of NSCLC who present locally advance primary tumor and 1-3 synchronous metastases in terms of response rate (RR), progression free survival (PFS) and overall survival (OS), and determine predictors of survival, in order to better guide clinical care and the design of future clinical trials
Summary
Non-Small-Cell Lung carcinoma (NSCLC) is the leading cause of cancer death worldwide [1]. Half of patients present with disseminated disease (stage IV); they are considered incurable and treated with palliative intent. An intermediate state between locally-advanced and metastatic disease has been proposed: The Oligometastatic disease [2,3,4]. This concept refers to cases with limited number of metastatic lesions, which in many cases can be treated with radical therapies such as surgery or radiotherapy [5] and could be considered a differentiated subgroup of patients.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
